Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai

Table 2

Diagnostic delays among MDR-TB patients, by history of tuberculosis and drug resistance pattern.

Variables	Total delay in DST		Delay in TB diagnosis		Health system delay in DST
	Median	IQR	Median	IQR	Median	IQR
All patients	136	88–235	33	19–56	92	50–192
History of tuberculosis treatment
Newly diagnosed	123	90–175	32	17.5–51.5	84.5	63.5–120
Relapsed	123	80–195	32	18–59	83	41–133
Chronic	420.5	110.5–873.5	33	20.5–54	297	47.5–821.5
value	<0.001		0.76		<0.001
Drug resistance pattern
Resistant to FLDs only	115	86–175	34	18–61	82	42–115
Resistant to FLDs and Ofx	173.5	90–440.5	37.5	18.5–64.5	111	37.5–339.5
Resistant to FLDs and injectable	149	124–356.5	28	20–50.5	113	90.5–247.5
XDR-TB	148	81–221	25	18–41	104	58–191
value	0.008		0.20		0.02

DST, drug susceptibility testing; IQR, inter quarter range; FLDs, first-line drugs; Ofx, ofloxacin; XDR-TB, extensively drug-resistant tuberculosis.
value: Kruskal-Wallis test.
The duration from onset of TB symptoms in the most recent disease episode to the date of reporting DST results.
The duration from TB diagnosis to the date of reporting DST results.
Including amikacin, kanamycin, and capreomycin.